Trial Profile

Phase 1b\2a study of CLR 121125 for the treatment of relapsed triple-negative breast cancer (TNBC).

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLR 121125 (Primary)
Indications Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

31 Oct 2025 New trial record
07 Oct 2025 According to Cellectar Biosciences media release, company enters Into agreements to raise $5.8 million.
09 Sep 2025 According to Cellectar Biosciences media release, the company plans to initiate Phase 1b Dose Finding study of Auger-emitting radiopharmaceutical, CLR 125, for the treatment of relapsed triple-negative breast cancer (TNBC) in e fourth quarter 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com